Clinical Trial Update: An Efficacy and Safety Study of Ontamalimab as Maintenance Therapy in Participants With Moderate to Severe Ulcerative Colitis [Phase 3]

View source ↗

Summary

Phase 3 trial update on ontamalimab as maintenance therapy for moderate-to-severe ulcerative colitis; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Ontamalimab (ontamalimab)

Snippet

Sponsor: Shire | Conditions: Ulcerative Colitis | Phase 3 | Status: COMPLETED | Results posted: 2022-01-14